Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania

Melissa S Cunningham, Emily Skrastins, Ryan Fitzpatrick, Priya Jindal, Olola Oneko, Karen Yeates, Christopher M Booth, Jennifer Carpenter, Kristan J Aronson, Melissa S Cunningham, Emily Skrastins, Ryan Fitzpatrick, Priya Jindal, Olola Oneko, Karen Yeates, Christopher M Booth, Jennifer Carpenter, Kristan J Aronson

Abstract

Objective: To determine cervical cancer screening coverage and the knowledge, attitudes and barriers toward screening tests among women in rural and urban areas of Tanzania, as well as explore how they view the acceptability of the HPV vaccine and potential barriers to vaccination.

Setting: A cross-sectional study using interview-administered questionnaires was conducted using multistage random sampling within urban and rural areas in Kilimanjaro Region, Tanzania.

Participants: Women aged 18-55 were asked to participate in the survey. The overall response rate was 97.5%, with a final sample of 303 rural and 272 urban dwelling women.

Primary and secondary outcome measures: Descriptive and simple test statistics were used to compare across rural and urban strata. Multivariate logistic regression models were used to estimate ORs and 95% CIs.

Results: Most women (82%) reported they had heard of cervical cancer, while self-reported cervical cancer screening among women was very low (6%). In urban areas, factors associated with screening were: older age (OR=4.14, 95% CI 1.86 to 9.24 for ages 40-49, and OR=8.38, 95% CI 2.10 to 33.4 for >50 years), having health insurance (OR=4.15, 95% CI 1.52 to 11.4), and having knowledge about cervical cancer (OR=5.81, 95% CI 1.58 to 21.4). In contrast, among women residing in rural areas, only condom use (OR=6.44, 95% CI 1.12 to 37.1) was associated with screening. Women from both rural and urban areas had low vaccine-related knowledge; however, most indicated they would be highly accepting if it were readily available (93%).

Conclusions: The current proportion of women screened for cervical cancer is very low in Kilimanjaro Region, and our study has identified several modifiable factors that could be addressed to increase screening rates. Although best implemented concurrently, the availability of prophylactic vaccination for girls may provide an effective means of prevention if they are unable to access screening in the future.

Keywords: Acceptability; Africa; Cervical Cancer; HPV; Vaccine.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

References

    1. De Sanjosé S, Serrano B, Castellsagué X, et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report [Internet]. 2012. .
    1. Schiffman M, Castle PE, Jeronimo J et al. . Human papillomavirus and cervical cancer. Lancet 2007;370:890–907. 10.1016/S0140-6736(07)61416-0
    1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J Sudbury Mass 2003;9:348–59. 10.1097/00130404-200309000-00004
    1. Yang BH, Bray FI, Parkin DM et al. . Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004;109:418–24. 10.1002/ijc.11719
    1. Nour NM. Cervical cancer: a preventable death. Rev Obstet Gynecol 2009;2:240–4.
    1. World Health Organization (WHO). Control of cancer of the cervix uteri. Bull World Health Organ 1986;64:607–18.
    1. WHO prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy [Internet]. WHO. (cited 26 August 2013).
    1. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med 2013;45:182–93. 10.3109/07853890.2011.645353
    1. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008;5:e132 10.1371/journal.pmed.0050132
    1. World Health Organization (WHO). Human papillomavirus vaccines WHO position paper. 2009 Apr 117–32. Report No 15.
    1. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Tanzania. (cited 30 May 2014). .
    1. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet 2010;376:572–3. 10.1016/S0140-6736(10)60881-1
    1. In her lifetime: female morbidity and mortality in Sub-Saharan Africa [Internet]. (cited 5 May 2014). .
    1. Harkness JA, van de Vijver FJR, Mohler PhP. Cross-cultural survey methods. J. Wiley; 2003:440.
    1. Fowler FJ. Survey research methods. SAGE Publications; 2009:201.
    1. Poss JE. Developing a new model for cross-cultural research: synthesizing the health belief model and the theory of reasoned action. Adv Nurs Sci 2001;23:1–15. 10.1097/00012272-200106000-00002
    1. Bursac Z, Gauss CH, Williams DK et al. . Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3:17 10.1186/1751-0473-3-17
    1. Lyimo FS, Beran TN. Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: three public policy implications. BMC Public Health 2012;12:22 10.1186/1471-2458-12-22
    1. Ibekwe CM, Hoque ME, Ntuli-Ngcobo B. Perceived susceptibility of cervical cancer screening among women attending Mahalapye district hospital, Botswana. South Afr J Epidemiol Infect 2010;25:16–21.
    1. National Bureau of Statistics, ICF Macro. Tanzania Demographic and Health Survey 2010 [Internet]. Dar es Salaam, Tanzania; 2011 Apr 482.
    1. Makwe CC, Anorlu RI, Odeyemi KA. Human papillomavirus (HPV) infection and vaccines: knowledge, attitude and perception among female students at the University of Lagos, Lagos, Nigeria. J Epidemiol Glob Heal 2012;2:199–206. 10.1016/j.jegh.2012.11.001
    1. Bigman CA, Cappella JN, Hornik RC. Effective or ineffective: attribute framing and the human papillomavirus (HPV) vaccine. Patient Educ Couns 2010;81(Suppl):S70–6. 10.1016/j.pec.2010.08.014
    1. Gerend MA, Shepherd JE. Using message framing to promote acceptance of the human papillomavirus vaccine. Health Psychol 2007;26:745–52. 10.1037/0278-6133.26.6.745
    1. Sperber NR, Brewer NT, Smith JS. Influence of parent characteristics and disease outcome framing on HPV vaccine acceptability among rural, Southern women. Cancer Causes Control 2007;19:115–18. 10.1007/s10552-007-9074-9
    1. Iliyasu Z, Abubakar IS, Aliyu MH et al. . Cervical cancer risk perception and predictors of human papilloma virus vaccine acceptance among female university students in northern Nigeria. J Obstet Gynaecol 2010;30:857–62. 10.3109/01443615.2010.511724
    1. Ports KA, Reddy DM, Rameshbabu A. Barriers and facilitators to HPV vaccination: perspectives from Malawian women. Women Health 2013;53:630–45. 10.1080/03630242.2013.809046
    1. Francis SA, Nelson J, Liverpool J et al. . Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine 2010;28:8026–32. 10.1016/j.vaccine.2010.08.090
    1. Francis SA, Battle-Fisher M, Liverpool J et al. . A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine 2011;29:8760–5. 10.1016/j.vaccine.2011.07.116
    1. Harries J, Moodley J, Barone MA et al. . Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009;27:38–44. 10.1016/j.vaccine.2008.10.033
    1. Coleman MA, Levison J, Sangi-Haghpeykar H. HPV vaccine acceptability in Ghana, West Africa. Vaccine 2011;29:3945–50. 10.1016/j.vaccine.2011.03.093
    1. DiAngi YT, Panozzo CA, Ramogola-Masire D et al. . A Cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS ONE 2011;6:e25481 10.1371/journal.pone.0025481
    1. Becker-Dreps S, Otieno WA, Brewer NT et al. . HPV vaccine acceptability among Kenyan women. Vaccine 2010;28:4864–7. 10.1016/j.vaccine.2010.05.034
    1. Katahoire RA, Jitta J, Kivumbi G et al. . An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr J Reprod Health [Internet]. 2008 (cited 7 Aug 2013);12.
    1. W Liu F, Vwalika B. Cervical cancer and HPV vaccination: knowledge and attitudes of adult women in Lusaka, Zambia. J Vaccines Vaccin [Internet] 2012 (cited 7 Aug 2013);3. 10.4172/2157-7560.1000138
    1. Omondi-Ogutu, M'Imunya JM. Parental acceptance of human papilloma virus vaccine for their pre-pubertal and teenage daughters. East Afr Med J 2013;88:163–70.
    1. Poole DN, Tracy JK, Levitz L et al. . A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS ONE 2013;8:e56402 10.1371/journal.pone.0056402
    1. Remes P, Selestine V, Changalucha J et al. . A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 2012;30:5363–7. 10.1016/j.vaccine.2012.06.025
    1. Rositch AF, Gatuguta A, Choi RY et al. . Knowledge and acceptability of Pap smears, self-sampling and HPV vaccination among adult women in Kenya. PLoS ONE 2012;7:e40766 10.1371/journal.pone.0040766
    1. Cunningham MS, Davison C, Aronson K. HPV vaccine acceptability: a systematic review. Prev Med 2014;69:274–9. 10.1016/j.ypmed.2014.08.035
    1. McFarland DM. Cervical cancer and Pap smear screening in Botswana: knowledge and perceptions. Int Nurs Rev 2003;50:167–75. 10.1046/j.1466-7657.2003.00195.x
    1. Basu P, Sarkar S, Mukherjee S et al. . Women's perceptions and social barriers determine compliance to cervical screening: results from a population based study in India. Cancer Detect Prev 2006;30:369–74. 10.1016/j.cdp.2006.07.004
    1. Ngugi CW, Boga H, Muigai AWT et al. . Factors affecting uptake of cervical cancer early detection measures among women in Thika, Kenya. Health Care Women Int 2012;33:595–613. 10.1080/07399332.2011.646367
    1. GAVI. Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals—2013—Press releases—News—Library—GAVI Alliance [Internet]. 2013 (cited 13 Aug 2013).
    1. Milstien J, David Griffin P, Lee JW. Damage to immunisation programmes from misinformation on contraceptive vaccines. Reprod Health Matters 1995;3:24–8. 10.1016/0968-8080(95)90155-8
    1. Watkins MM, Gabali C, Winkleby M et al. . Barriers to cervical cancer screening in rural Mexico. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2002;12:475–9. 10.1046/j.1525-1438.2002.01170.x
    1. Lin S-J. Factors influencing the uptake of screening services for breast and cervical cancer in Taiwan. J R Soc Promot Heal 2008;128:327–34. 10.1177/1466424007092802
    1. Akinyemiju TF. Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the World Health Survey. PLoS ONE 2012;7:e48834 10.1371/journal.pone.0048834
    1. Gamarra CJ, Paz EPA, Griep RH. Social support and cervical and breast cancer screening in Argentinean women from a rural population. Public Health Nurs 2009;26:269–76. 10.1111/j.1525-1446.2009.00779.x
    1. Abotchie PN, Shokar NK. Cervical cancer screening among college students in Ghana: knowledge and health beliefs. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2009;19:412–16. 10.1111/IGC.0b013e3181a1d6de
    1. Byrd TL, Chavez R, Wilson KM. Barriers and facilitators of cervical cancer screening among Hispanic women. Ethn Dis 2007;17:129–34.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다